Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (e13a2 and/or e14a2) or minor p190 (e1a2) fusion proteins with option to add p230 detection (micro or atypical variant). Analytical sensitivity is 0.002% for p210 and 0.005% for p190, depending on quality and quantity of the isolated RNA and absence of interfering substances. Log reduction score and percent abnormal are reported, and longitudinal data will appear as a NeoTRACK Result on the report. Testing is New York approved for p210 and p190 only. p230 testing may be ordered as a reflex if p210 and p190 are negative, or as a stand-alone test, BCR-ABL1 Non-Standard p230. For p230, results are reported as percent abnormal.
Useful for diagnosis and monitoring of Philadelphia chromosome-positive cases of CML and ALL. Also useful for monitoring minimal residual disease (MRD) for ALL and AML.
- Bone Marrow: 2 mL EDTA tube. Sodium heparin acceptable.
- Peripheral Blood: 5 mL EDTA tube. Sodium heparin acceptable.
Note: Test is RNA-based, NOT suitable for Freeze & Hold option.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.